ADA updates its “living” standards of medical care in DM

The updates are:

• Section 10 was updated based on the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), in which icosapent ethyl (Vascepa) added to statin therapy for patients with high triglyceride levels reduced cardiovascular events.
  • Standards now include a recommendation that icosapent ethyl be considered for patients with diabetes and atherosclerotic cardiovascular disease or other cardiac risk factors on a statin with controlled low-density lipoprotein cholesterol, but with elevated triglycerides (135-499 mg/dL) to reduce cardiovascular risk.
• Several revisions in sections 9, 10, and 11 were based on outcomes from The Dapagliflozin Effect on Cardiovascular Events-Thrombosis in Myocardial Infarction 58 (DECLARE-TIMI 58) Trial, in which dapagliflozin (Farxiga) reduced both hospitalization for heart failure and CKD progression.
• Based on a revision to dapagliflozin prescribing information for patients with diabetes and CKD, the approved use per estimated glomerular filtration rate has been revised from ≥60 mL/minute/1.73 m² to ≥45 mL/minute/1.73 m² in Section 11.